Buparlisib (AN2025)
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Key Facts
About Adlai Nortye
Adlai Nortye is a Cayman Islands-incorporated, China and US-based biotech company dedicated to discovering and developing novel anti-cancer treatments. Its strategy centers on advancing buparlisib, a drug with a history in other cancers, into a new pivotal indication (HNSCC) while building a broader pipeline targeting the tumor microenvironment. The company went public on the NASDAQ in 2023, raising capital to fund its late-stage clinical development and expand its research efforts.
View full company profileAbout Adlai Nortye
Adlai Nortye is a Cayman Islands-incorporated, China and US-based biotech company dedicated to discovering and developing novel anti-cancer treatments. Its strategy centers on advancing buparlisib, a drug with a history in other cancers, into a new pivotal indication (HNSCC) while building a broader pipeline targeting the tumor microenvironment. The company went public on the NASDAQ in 2023, raising capital to fund its late-stage clinical development and expand its research efforts.
View full company profile